Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation

Jeffrey J. Kim, William J. Dreyer, E. O'Brian Smith, Jack F. Price, Sarah Clunie, V. Vasiliki Dimas, John Jefferies, Howard Rosenblatt, Branislav Radovancevic, Jeffrey Towbin, Susan W. Denfield

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Leukocyte suppression is a sequela of immunosuppressive therapy after orthotopic heart transplantation and may result in discontinuation of anti-proliferative agents. Clinical outcomes in this patient population have not been well delineated. Methods: This study was a retrospective review of children who underwent orthotopic heart transplantation at our institution from 1986 to 2003. Leukocyte suppression was defined as a white blood cell count <5,000, prompting the withdrawal of anti-proliferative agents. The population was divided into 2 groups, leukosuppressed (LS) and non-leukosuppressed (NLS), and their clinical outcomes were compared. Results: The study included 109 patients, of which 44 (40%) became leukosuppressed. The 2 groups were similar regarding demographic data and initial management. The LS Group had a significantly decreased incidence of rejection, being 7 times less likely to have recurrent rejection (p = 0.001). The median time to rejection was 0.8 ± 0.6 years for the NLS Group, whereas the median time to rejection was not yet reached at 17 years for the LS Group. The LS Group also tended toward a decreased incidence of retransplantation or death (p = 0.06). The organ "half-life" in the NLS Group was 7.5 years vs 12.5 years in the LS Group. There was no difference between the 2 groups in regards to other adverse effects of immunosuppression. Conclusions: Children who have undergone orthotopic heart transplantation and subsequently become leukosuppressed have a lower incidence of rejection and a tendency toward less organ loss than children who do not become leukosuppressed, without having an increased incidence of adverse side effects.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalJournal of Heart and Lung Transplantation
Volume25
Issue number2
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Heart Transplantation
Leukocytes
Incidence
Immunosuppressive Agents
Leukocyte Count
Immunosuppression
Population
Half-Life
Demography
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation. / Kim, Jeffrey J.; Dreyer, William J.; O'Brian Smith, E.; Price, Jack F.; Clunie, Sarah; Dimas, V. Vasiliki; Jefferies, John; Rosenblatt, Howard; Radovancevic, Branislav; Towbin, Jeffrey; Denfield, Susan W.

In: Journal of Heart and Lung Transplantation, Vol. 25, No. 2, 01.01.2006, p. 195-199.

Research output: Contribution to journalArticle

Kim, JJ, Dreyer, WJ, O'Brian Smith, E, Price, JF, Clunie, S, Dimas, VV, Jefferies, J, Rosenblatt, H, Radovancevic, B, Towbin, J & Denfield, SW 2006, 'Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation', Journal of Heart and Lung Transplantation, vol. 25, no. 2, pp. 195-199. https://doi.org/10.1016/j.healun.2005.09.005
Kim, Jeffrey J. ; Dreyer, William J. ; O'Brian Smith, E. ; Price, Jack F. ; Clunie, Sarah ; Dimas, V. Vasiliki ; Jefferies, John ; Rosenblatt, Howard ; Radovancevic, Branislav ; Towbin, Jeffrey ; Denfield, Susan W. / Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation. In: Journal of Heart and Lung Transplantation. 2006 ; Vol. 25, No. 2. pp. 195-199.
@article{09649b687e8744719cbc9b5ff38a700f,
title = "Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation",
abstract = "Background: Leukocyte suppression is a sequela of immunosuppressive therapy after orthotopic heart transplantation and may result in discontinuation of anti-proliferative agents. Clinical outcomes in this patient population have not been well delineated. Methods: This study was a retrospective review of children who underwent orthotopic heart transplantation at our institution from 1986 to 2003. Leukocyte suppression was defined as a white blood cell count <5,000, prompting the withdrawal of anti-proliferative agents. The population was divided into 2 groups, leukosuppressed (LS) and non-leukosuppressed (NLS), and their clinical outcomes were compared. Results: The study included 109 patients, of which 44 (40{\%}) became leukosuppressed. The 2 groups were similar regarding demographic data and initial management. The LS Group had a significantly decreased incidence of rejection, being 7 times less likely to have recurrent rejection (p = 0.001). The median time to rejection was 0.8 ± 0.6 years for the NLS Group, whereas the median time to rejection was not yet reached at 17 years for the LS Group. The LS Group also tended toward a decreased incidence of retransplantation or death (p = 0.06). The organ {"}half-life{"} in the NLS Group was 7.5 years vs 12.5 years in the LS Group. There was no difference between the 2 groups in regards to other adverse effects of immunosuppression. Conclusions: Children who have undergone orthotopic heart transplantation and subsequently become leukosuppressed have a lower incidence of rejection and a tendency toward less organ loss than children who do not become leukosuppressed, without having an increased incidence of adverse side effects.",
author = "Kim, {Jeffrey J.} and Dreyer, {William J.} and {O'Brian Smith}, E. and Price, {Jack F.} and Sarah Clunie and Dimas, {V. Vasiliki} and John Jefferies and Howard Rosenblatt and Branislav Radovancevic and Jeffrey Towbin and Denfield, {Susan W.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/j.healun.2005.09.005",
language = "English (US)",
volume = "25",
pages = "195--199",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation

AU - Kim, Jeffrey J.

AU - Dreyer, William J.

AU - O'Brian Smith, E.

AU - Price, Jack F.

AU - Clunie, Sarah

AU - Dimas, V. Vasiliki

AU - Jefferies, John

AU - Rosenblatt, Howard

AU - Radovancevic, Branislav

AU - Towbin, Jeffrey

AU - Denfield, Susan W.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: Leukocyte suppression is a sequela of immunosuppressive therapy after orthotopic heart transplantation and may result in discontinuation of anti-proliferative agents. Clinical outcomes in this patient population have not been well delineated. Methods: This study was a retrospective review of children who underwent orthotopic heart transplantation at our institution from 1986 to 2003. Leukocyte suppression was defined as a white blood cell count <5,000, prompting the withdrawal of anti-proliferative agents. The population was divided into 2 groups, leukosuppressed (LS) and non-leukosuppressed (NLS), and their clinical outcomes were compared. Results: The study included 109 patients, of which 44 (40%) became leukosuppressed. The 2 groups were similar regarding demographic data and initial management. The LS Group had a significantly decreased incidence of rejection, being 7 times less likely to have recurrent rejection (p = 0.001). The median time to rejection was 0.8 ± 0.6 years for the NLS Group, whereas the median time to rejection was not yet reached at 17 years for the LS Group. The LS Group also tended toward a decreased incidence of retransplantation or death (p = 0.06). The organ "half-life" in the NLS Group was 7.5 years vs 12.5 years in the LS Group. There was no difference between the 2 groups in regards to other adverse effects of immunosuppression. Conclusions: Children who have undergone orthotopic heart transplantation and subsequently become leukosuppressed have a lower incidence of rejection and a tendency toward less organ loss than children who do not become leukosuppressed, without having an increased incidence of adverse side effects.

AB - Background: Leukocyte suppression is a sequela of immunosuppressive therapy after orthotopic heart transplantation and may result in discontinuation of anti-proliferative agents. Clinical outcomes in this patient population have not been well delineated. Methods: This study was a retrospective review of children who underwent orthotopic heart transplantation at our institution from 1986 to 2003. Leukocyte suppression was defined as a white blood cell count <5,000, prompting the withdrawal of anti-proliferative agents. The population was divided into 2 groups, leukosuppressed (LS) and non-leukosuppressed (NLS), and their clinical outcomes were compared. Results: The study included 109 patients, of which 44 (40%) became leukosuppressed. The 2 groups were similar regarding demographic data and initial management. The LS Group had a significantly decreased incidence of rejection, being 7 times less likely to have recurrent rejection (p = 0.001). The median time to rejection was 0.8 ± 0.6 years for the NLS Group, whereas the median time to rejection was not yet reached at 17 years for the LS Group. The LS Group also tended toward a decreased incidence of retransplantation or death (p = 0.06). The organ "half-life" in the NLS Group was 7.5 years vs 12.5 years in the LS Group. There was no difference between the 2 groups in regards to other adverse effects of immunosuppression. Conclusions: Children who have undergone orthotopic heart transplantation and subsequently become leukosuppressed have a lower incidence of rejection and a tendency toward less organ loss than children who do not become leukosuppressed, without having an increased incidence of adverse side effects.

UR - http://www.scopus.com/inward/record.url?scp=31544473105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544473105&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2005.09.005

DO - 10.1016/j.healun.2005.09.005

M3 - Article

VL - 25

SP - 195

EP - 199

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 2

ER -